Showing results (11-20 of 39) with videos related to
Sort By:
Pageof 4
Breast Cancer Research and Treatment|March 24, 2018
Breast cancer survival, survival disparities, and guideline-based treatmentDeirdre A Hill, Sarah Friend, Lesley Lomo, et al.BMC Cancer|May 21, 2005
Minimum follow-up time required for the estimation of statistical cure of cancer patients: verification using data from 42 cancer sites in the SEER databasePatricia Tai, Edward Yu, Gábor Cserni, et al.Cytokine|April 27, 2010
Polymorphisms in cytokine genes and serum cytokine levels among New Mexican women with and without breast cancerEsther Erdei, Huining Kang, Angela Meisner, et al.American Journal of Clinical Oncology|November 4, 2009
A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancerHouman M Fekrazad, Claire F Verschraegen, Melanie Royce, et al.Breast Cancer Research and Treatment|March 5, 2011
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumabStefan Glück, Jeffrey S Ross, Melanie Royce, et al.Journal of Magnetic Resonance Imaging : JMRI|July 12, 2012
Quantitative mapping of total choline in healthy human breast using proton echo planar spectroscopic imaging (PEPSI) at 3 TeslaChenguang Zhao, Patrick J Bolan, Melanie Royce, et al.Breast Cancer Research and Treatment|March 2, 2011
Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patientsNabila Chaher, Hugo Arias-Pulido, Nadija Terki, et al.Journal of Community Genetics|October 4, 2017
Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative familiesBelinda Vicuña, Harold D Delaney, Kristina G Flores, et al.Cancer|August 28, 2003
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinomaFrancisco J Esteva, Edgardo Rivera, Massimo Cristofanilli, et al.Plos One|April 25, 2009
Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cellsJustin Wray, Elizabeth A Williamson, Melanie Royce, et al.Pageof 4